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timOBJECTIVES This study sought to determine whether pre–percutaneous coronary intervention (PCI) plaque charac-
terization using near-infrared spectroscopy identiﬁes lipid-rich plaques at risk of periprocedural myonecrosis and whether
these events may be prevented by the use of a distal protection ﬁlter during PCI.
BACKGROUND Lipid-rich plaques may be prone to distal embolization and periprocedural myocardial infarction (MI) in
patients undergoing PCI.
METHODS Patients undergoing stent implantation of a single native coronary lesion were enrolled in a multicenter,
prospective trial. Near-infrared spectroscopy and intravascular ultrasound were performed at baseline, and lesions with a
maximal lipid core burden index over any 4-mm length (maxLCBI4mm)$600 were randomized to PCI with versus without
a distal protection ﬁlter. The primary endpoint was periprocedural MI, deﬁned as troponin or a creatine kinase-myocardial
band increase to 3 or more times the upper limit of normal.
RESULTS Eighty-ﬁve patients were enrolled at 9 U.S. sites. The median (interquartile range) maxLCBI4mm was 448.4
(274.8 to 654.4) pre-PCI and decreased to 156.0 (75.6 to 312.6) post-PCI (p < 0.0001). Periprocedural MI developed in
21 patients (24.7%). The maxLCBI4mm was higher in patients with versus without MI (481.5 [425.6 to 679.6] vs. 371.5
[228.9 to 611.6], p ¼ 0.05). Among 31 randomized lesions with maxLCBI4mm $600, there was no difference in the rates
of periprocedural MI with versus without the use of a distal protection ﬁlter (35.7% vs. 23.5%, respectively; relative risk:
1.52; 95% conﬁdence interval: 0.50 to 4.60, p ¼ 0.69).
CONCLUSIONS Plaque characterization by near-infrared spectroscopy identiﬁes lipid-rich lesions with an increased
likelihood of periprocedural MI after stent implantation, presumably due to distal embolization. However, in this
pilot randomized trial, the use of a distal protection ﬁlter did not prevent myonecrosis after PCI of lipid-rich plaques.
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AND ACRONYMS
EEM = external elastic
membrane
IVUS = intravascular
ultrasound
LCBI = lipid core burden index
LRP = lipid-rich plaque
maxLCBI4mm = maximal lipid
core burden index over any
4-mm length
MI = myocardial infarction
MLA = minimal lumen area
NIRS = near-infrared
spectroscopy
PCI = percutaneous coronary
intervention
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928P eriprocedural myonecrosis is com-mon after percutaneous coronaryintervention (PCI), occurring in as
many as 40% of patients (1,2). Although the
threshold of post-PCI biomarker elevation
that is prognostically relevant is controver-
sial (3,4), there is general agreement that
any level of periprocedural myonecrosis is
undesirable. Previous studies have identiﬁedSEE PAGE 946baseline clinical and angiographic lesion
characteristics that are associated with intra-
procedural thrombotic events and post-PCI
myocardial infarction (MI) (5–8). Beyond
these conventional features, certain plaque
phenotypes may be particularly susceptibleto distal embolization, microvascular obstruction,
and myonecrosis after PCI. Speciﬁcally, lipid-rich
ﬁbroatheromas are friable and easily disrupted during
PCI, predisposing to periprocedural MI (9). Over the
past several years, case reports and uncontrolled or
retrospective registries have suggested that plaque
characterization by invasive imaging with gray-scale
and radiofrequency intravascular ultrasound (IVUS),
optical coherence tomography, and near-infrared
spectroscopy (NIRS) may identify emboli-prone le-
sions (10–16). Moreover, distal protection devices
have been shown to prevent embolization and reduce
periprocedural myonecrosis after PCI of friable saphe-
nous vein graft lesions (17,18). Brilakis et al. (19) re-
ported that use of a ﬁlter-based catheter in the
native coronary circulation before PCI of high-risk
plaques may protect the distal microvasculature
from embolization. Whether native coronary artery
lesions prone to periprocedural myonecrosis can be
identiﬁed before PCI and whether the use of a distal
embolic protection device can reduce the incidence
of periprocedural MI in high-risk lesions so identiﬁed
have never been prospectively examined in a multi-
center trial.
The TVC catheter (InfraReDx, Inc., Burlington,
Massachusetts) is a U.S. Food and Drug Adminis-
tration–approved dual-modality intravascular imag-
ing device that coregisters a NIRS chemogram to
a gray-scale IVUS image, allowing simultaneous
assessment of plaque morphology and composi-
tion. NIRS has been validated to accurately identifytt Vascular, Elsevier, Somahlution, and Boston Scientiﬁc; has rec
s spouse is an employee of Medtronic. All other authors have rep
this paper to disclose.
received November 9, 2014; revised manuscript received Decemﬁbroatheromas in humans (20) and provides an
automated quantitative assessment of lipid burden
in lipid-rich plaques (LRPs). We therefore sought to
determine whether pre-PCI plaque characterization
using NIRS is capable of identifying lesions at risk
of periprocedural myonecrosis and whether these
events may be prevented by the use of a distal
protection ﬁlter during PCI in the native coronary
circulation.
METHODS
PROTOCOL OVERVIEW. The CANARY (Coronary As-
sessment by Near-infrared of Atherosclerotic Rupture-
prone Yellow) trial was a prospective, multicenter,
randomized pilot trial designed to determine the
relationship between NIRS lipid parameters and sub-
sequent periprocedural myonecrosis after coronary
stenting and whether the use of the FilterWire EZ
(21) distal protection ﬁlter (Boston Scientiﬁc, Natick,
Massachusetts) can reduce MI after PCI of LRPs.
Patients with stable angina, silent ischemia,
or stabilized acute coronary syndromes who had
troponin I or T and creatine kinase-myocardial band
levels all less than the local laboratory upper limit of
normal within 12 h of the time of PCI were eligible for
enrollment. Major clinical exclusion criteria included
previous coronary artery bypass graft surgery, previ-
ous PCI within 24 h or future planned PCI within
30 days, left ventricular ejection fraction <25%, and
the inability to take aspirin and a thienopyridine for
at least 30 days. Angiographic inclusion criteria
required planned PCI of a single de novo lesion in a
native coronary artery with reference vessel diameter
of $2.5 mm, diameter stenosis of $50% to <100%,
and length of #60 mm. In addition, a nondiseased
landing zone for the FilterWire EZ with a $2.5 mm
reference diameter must be present $2.5 cm distal to
the target lesion, and there could be no side branches
greater than 2.0 mm in diameter within the target
lesion or between the target lesion and the ﬁlter
loop landing zone (21). Other angiographic exclu-
sion criteria included a greater than 50% diameter
stenosis in the left main coronary artery or left main
equivalent disease or the presence of any of the
following target lesion characteristics: ostial location;
thrombus; or severe calciﬁcation. The study was
approved by the investigational review board ateived research support from Guerbet and InfraReDx;
orted that they have no relationships relevant to the
ber 23, 2014, accepted January 1, 2015.
FIGURE 1 Representative Case
Baseline
Post-Stent
= 662
= 322
Baseline: A moderately severe stenosis is present in the mid left anterior descending
coronary artery (white arrow). The lesion was characterized by near infrared spectroscopy
and intravascular ultrasound as a calciﬁed lipid-rich plaque with minimal lumen area (MLA)
of 3.1 mm2, plaque burden of 74.2%, lipid core burden index (LCBI) of 229 and maximal
lipid core burden index over any 4-mm length (maxLCBI4mm) of 662. Post-stent: After
placement of a 3.0-mm diameter  28-mm long stent and post-dilation with a non-
compliant 3.0-mm diameter balloon at 20 atm, the MLA increased to 6.2 mm2 and the
LCBI and maxLCBI4mm decreased to 113 and 322, respectively, consistent with distal
embolization. Troponin I increased from 0 at baseline to 3.8 ng/ml post-procedure,
meeting criteria for a periprocedural myocardial infarction.
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929each institution, and all patients provided written
informed consent before enrollment.
All patients received $81 mg aspirin orally at least
2 h before the procedure. A loading dose of an aden-
osine diphosphate receptor antagonist was strongly
recommended pre-PCI, but in all cases was adminis-
tered within 2 h post-procedure. Anticoagulation was
achieved with either intravenous heparin or bivalir-
udin, with glycoprotein IIb/IIIa inhibitor use allowed
per operator discretion.
After diagnostic angiography, NIRS-IVUS was per-
formed with a 3.2-F TVC catheter from the distal
target vessel to the guide catheter using a motorized
pullback system at 0.5 mm/s. The locations of major
side branches and the target lesion boundaries were
marked and annotated during pullback using TVC
system software. The total lesion lipid core burden
index (LCBI) and maximal LCBI over any 4 mm
segment (maxLCBI4mm) were then automatically
calculated as previously described (16). In summary,
raw spectroscopic data are converted into a proba-
bility of LRP on a red-to-yellow color scale, with
red representing low probability of lipid and yellow
representing high probability. LCBI represents
the proportion of yellow pixels (lipid probability
>0.6) in the plaque, reported on a scale of 0 to
1,000 (signifying 0% to 100% lipid). The number
of yellow pixels every 0.1 mm was determined by
the automated software and summed over each
possible 4-mm long axial segment to determine the
maxLCBI4mm (Online Figure 1).
LRPs were pre-speciﬁed as those with maxLCBI4mm
$600. LRPs were randomized 1:1 to PCI and stenting
with versus without use of the FilterWire EZ dis-
tal protection device. For patients randomized to
distal protection, the FilterWire EZ was required
to be deployed for all interventions (balloon angio-
plasty and stenting). PCI with stenting was other-
wise performed using standard techniques. Non-LRPs
(maxLCBI4mm <600) underwent PCI without distal
protection. After the ﬁnal PCI, NIRS-IVUS imaging was
repeated. A representative case is shown in Figure 1.
Creatine kinase-myocardial band and troponin I or
T measurements were obtained at 8 and 16 h post-
procedure in all patients and for any recurrent
chest discomfort or other signs or symptoms of clin-
ical instability. Patients were maintained on daily
aspirin $81 mg and an adenosine diphosphate
receptor antagonist for at least 30 days.
ENDPOINTS. The primary endpoint was the incidence
of periprocedural MI, deﬁned as troponin or creatine
kinase-myocardial band increase to 3 or more times
the upper limit of normal within 72 h. Additionalin-hospital endpoints included death (cardiac and
noncardiac), any MI, target vessel revascularization,
and stent thrombosis. All events were adjudicated by
a clinical events committee blinded to NIRS mea-
surement and randomization. Quantitative coronary
angiography was performed at an independent core
laboratory using standardized methodology. Gray-
scale IVUS parameters were assessed by a blinded
core laboratory as previously described (22). Quanti-
tative IVUS measurements included external elastic
membrane (EEM) cross-sectional area, plaque and
media (EEM minus lumen) cross-sectional area,
plaque burden (plaque and media divided by EEM
cross-sectional area), and minimal lumen area (MLA).
Measurements were taken both at the site of the MLA
within the entire lesion and at the MLA site within the
maxLCBI4mm segment. Attenuated plaque was deﬁned
as hypoechoic plaque with deep ultrasound attenua-
tion without calciﬁcation or very dense ﬁbrous plaque
(12). The same core laboratory determined the LCBI,
maxLCBI4mm, and the lipid-rich plaque burden,
FIGURE 2 Patient
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930deﬁned as the proportion of plaque-containing lipid
(Online Figure 2).
STATISTICAL METHODOLOGY. Sample size was
determined to show a reduction in periprocedural MI
with FilterWire EZ use in LRPs. Given the restrictive
enrollment criteria, a large effect size was assumed
for this pilot study, the presence of which would be
required to proceed to a pivotal trial. Anticipating a
doubling of the periprocedural MI rate in LRPs
compared with non-LRPs and the sensitive deﬁnition
of MI being used, an event rate of 56% was assumed
in the LRP control arm on the basis of historical
control values (1–3). Randomizing 54 patients (27 in
each group) would provide 80% power to show a
reduction to 20% in the FilterWire EZ arm using a 2-
sided alpha of 0.05. Thus, the study was planned to
enroll up to 108 patients, including 54 randomized
LRPs and 54 nonrandomized non-LRPs.
Categorical variables were compared using the chi-
square or Fisher exact test. Continuous variables are
displayed as median (interquartile range) and were
compared using Student t test or the Wilcoxon rank
sum test for non-normally distributed data. Receiver-
operating characteristic curves were drawn and the
cutoffs determined that best balanced sensitivity and
speciﬁcity between NIRS parameters and periproce-
dural MI by identifying the point closest to (0,1) on
the receiver-operating characteristic curve. AllFlow Diagram
tients, 85 were enrolled (12.0%). Among excluded patients, more
ria were present in some patients, and infrequent exclusion criteria are
t. After near-infrared spectroscopy was performed in the 85 enrolled
ts were stratiﬁed to the randomized group (maxLCBI4mm $600) or
axLCBI4mm <600). maxLCBI4mm ¼ maximal lipid core burden index
h; PCI ¼ percutaneous coronary intervention; RVD ¼ reference vesselanalyses are by intention-to-treat. All p values are
2-sided, and p < 0.05 was considered statistically
signiﬁcant.
RESULTS
PATIENTS AND ENROLLMENT. A total of 709 patients
were prospectively screened at 8 U.S. sites, of whom
85 (12.0%) with qualifying lesions undergoing PCI
were enrolled (Figure 2). A single site (Mount Sinai
Hospital, New York, New York) enrolled 51 patients,
whereas the other centers enrolled between 2 and 9
patients each. The maxLCBI4mm was $600 in 31 le-
sions (36.5%), which were then randomized to PCI
with (n ¼ 14) and without (n ¼ 17) distal protection
with the FilterWire EZ. In the other 54 lesions, PCI
was performed without distal protection. Because of
difﬁcult recruitment, the Data Safety and Monitoring
Board reviewed the unblinded data after the 31 LRP
lesions were randomized and recommended that the
trial be terminated for futility (lack of evidence of any
randomized treatment beneﬁt).
Baseline clinical, angiographic, IVUS, and NIRS
characteristics of the randomized and registry groups
are shown in Tables 1 to 3. LCBI and maxLCBI4mm
were by deﬁnition substantially greater in the ran-
domized (LRP) cohort compared with the registry
(non-LRP) cohort (Table 3). In most other respects, the
groups were not signiﬁcantly different. Compared
with the registry, randomized lesions were somewhat
more severe by angiography but not by IVUS. The
frequency of attenuated plaques was also similar in
the 2 groups, although the length and angle of atten-
uation were greater in the randomized group, as were
measures of LRP burden, again consistent with the
stratiﬁcation. Baseline features were well balanced
among the LRP patients and lesions randomized to
FilterWire EZ versus control group (Tables 1 to 3),
although the FilterWire group had slightly more left
anterior descending artery lesions but had shorter
length of stents placed. NIRS and IVUS parameters
were similar in the 2 randomized groups.
Stents were implanted in all patients. Consid-
ering all 85 lesions, the median (interquartile range)
maxLCBI4mm decreased from 448.4 (274.8 to 654.4)
pre-PCI to 156.0 (75.6 to 312.6) post-PCI, and the total
lesion LCBI decreased from 143.2 (74.3 to 236.4) to
17.9 (0.0 to 61.9) (p < .0001 for each comparison).
PERIPROCEDURAL MI AND ADDITIONAL CLINICAL
EVENTS. Periprocedural MI developed in 21 of 85
patients (24.7%) (Figure 3). All were non–Q-wave
MIs. Periprocedural MI according to the Third Uni-
versal MI deﬁnition (23) and the Society of Cardiac
TABLE 1 Baseline Clinical Characteristics and Procedural Medications
All Patients
(N ¼ 85)
Registry
(n ¼ 54)
Randomized
(n ¼ 31) p1 Value
Randomized
FilterWire EZ
(n ¼ 14)
Randomized No
FilterWire EZ
(n ¼ 17) p2 Value
Age, yrs 63.0 (56.0–69.0) 63.5 (56.0–69.0) 63.0 (56.0–69.0) 0.59 61.5 (52.0–69.0) 64.0 (57.0–66.0) 0.63
Female 15 (17.6) 8 (14.8) 7 (22.6) 0.37 5 (35.7) 2 (11.8) 0.20
Body mass index, kg/m2 29.1 (26.2–32.6) 29.1 (26.3–32.6) 28.4 (24.8–34.6) 0.42 26.6 (24.4–30.4) 29.4 (27.2–34.6) 0.30
Diabetes 28 (32.9) 19 (35.2) 9 (29.0) 0.56 5 (35.7) 4 (23.5) 0.69
Hypertension 77 (90.6) 50 (92.6) 27 (87.1) 0.46 13 (92.9) 14 (82.4) 0.61
Hyperlipidemia 78 (91.8) 51 (94.4) 27 (87.1) 0.25 12 (85.7) 15 (88.2) 1.0
Smoking, current 13 (15.3) 6 (11.1) 7 (22.6) 0.21 4 (28.6) 3 (17.6) 0.67
Previous myocardial infarction 19 (22.4) 12 (22.2) 7 (22.6) 0.97 3 (21.4) 4 (23.5) 1.0
Previous PCI 44 (51.8) 30 (55.6) 14 (45.2) 0.36 7 (50.0) 7 (41.2) 0.62
Presentation
STEMI 1 (1.2) 0 (0) 1 (3.2) 0.36 0 (0) 1 (5.9) 1.0
Non-STEMI 5 (5.9) 4 (7.4) 1 (3.2) 0.65 0 (0) 1 (5.9) 1.0
Unstable angina, troponin negative 46 (54.1) 27 (50.0) 19 (61.3) 0.31 11 (78.6) 8 (47.1) 0.07
Stable angina or silent ischemia 33 (38.8) 23 (42.6) 10 (32.3) 0.35 3 (21.4) 7 (41.2) 0.28
Procedural/discharge medications
Aspirin 85 (100.0) 54 (100.0) 31 (100.0) — 14 (100) 17 (100) —
ADP receptor antagonist 85 (100.0) 54 (100.0) 31 (100.0) — 14 (100) 17 (100) —
Clopidogrel 69 (81.2) 43 (79.6) 26 (83.9) 0.63 12 (85.7) 14 (82.4) 1.0
Prasugrel or ticagrelor 16 (18.8) 11 (20.4) 5 (16.1) 0.63 2 (14.3) 3 (17.7) 1.0
Statin 73 (85.9) 49 (90.7) 24 (7.4) 0.11 12 (85.7) 12 (70.6) 0.41
Heparin 5/76 (6.6) 3/48 (5.9) 2/28 (7.1) 1.0 1/12 (8.3) 1/16 (6.3) 1.0
Bivalirudin 71/76 (93.4) 45/48 (94.1) 26/28 (92.9) 1.0 11/12 (91.7) 15/16 (93.7) 1.0
Glycoprotein IIb/IIIa inhibitor* 4/83 (4.8) 1/52 (1.9) 3 (9.7) 0.14 2 (14.3) 1 (5.9) 0.58
Values are n (%), median (interquartile range), or n/N (%). *All eptiﬁbatide.
ADP ¼ adenosine diphosphate; PCI ¼ percutaneous coronary intervention; p1 value ¼ randomized vs. registry; p2 value ¼ FilterWire EZ vs. control.
TABLE 2 Baseline Angiographic and Procedural Characteristics
All Patients
(N ¼ 85)
Registry
(n ¼ 54)
Randomized
(n ¼ 31) p1 Value
Randomized
FilterWire EZ
(n ¼ 14)
Randomized No
FilterWire EZ
(n ¼ 17) p2 Value
Stents implanted 85 (100) 54 (100) 31 (100) — 14 (100) 17 (100) —
Drug-eluting stents 84 (98.8) 53 (98.1) 31 (100) 1.0 14 (100) 17 (100) —
Total stent length, mm 28 (22–38) 28 (22–40) 26 (20–38) 0.43 23 (18–26) 33 (23–38) 0.03
Maximal device diameter, mm 3.5 (3.0–3.5) 3.5 (3.0–3.5) 3.5 (3.0–4.0) 0.30 3.5 (3.3–4.0) 3.5 (3.0–3.5) 0.24
Maximal inﬂation pressure, atm 16 (14–18) 16 (14–20) 16 (14–18) 0.28 16 (14–18) 16 (14–18) 1.0
Quantitative coronary angiography n ¼ 78 n ¼ 48 n ¼ 30 n ¼ 14 n ¼ 16
Lesion location
Left anterior descending 44 (56.4) 27 (56.3) 17 (56.7) 0.97 11 (78.6) 6 (37.5) 0.02
Left circumﬂex 12 (15.4) 9 (18.8) 3 (10.0) 0.35 0 (0) 3 (18.8) 0.23
Right coronary artery 22 (28.2) 12 (25.0) 10 (33.3) 0.43 3 (21.4) 7 (43.8) 0.26
Pre-PCI measurements
Reference vessel diameter, mm 2.79 (2.59–3.23) 2.88 (2.59–3.24) 2.73 (2.59–3.23) 0.68 2.76 (2.70–3.26) 2.70 (2.49–3.18) 0.67
Minimal luminal diameter, mm 1.05 (0.66–1.36) 1.14 (0.72–1.41) 0.73 (0.54–1.10) 0.002 0.82 (0.70–0.97) 0.61 (0.51–1.17) 0.79
Diameter stenosis, % 63.0 (54.9–77.2) 57.3 (53.6–72.1) 73.8 (63.0–80.3) 0.0006 73.8 (61.9–77.2) 74.9 (64.1–81.2) 0.82
Lesion length, mm 15.8 (12.1–22.3) 15.5 (12.1–20.7) 16.4 (11.9–24.0) 0.63 15.1 (11.1–18.7) 22.3 (12.2–27.0) 0.10
Bifurcation lesion 22 (28.2) 10 (20.8) 12 (40.0) 0.07 8 (57.1) 4 (25.0) 0.07
Thrombus present 3 (3.8) 1 (2.1) 2 (6.7) 0.56 0 (0) 2 (12.5) 0.49
Moderate or severe calciﬁcation* 24 (30.8) 18 (37.5) 6 (20.0) 0.10 3 (21.4) 3 (18.8) 1.0
Values are n (%) or median (interquartile range). *Graded as moderate in all patients.
Abbreviations as in Table 1.
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TABLE 3 Baseline NIRS and IVUS Measurements
All Patients
(N ¼ 83)
Registry
(n ¼ 52)
Randomized
(n ¼ 31) p1 Value
Randomized
FilterWire EZ
(n ¼ 14)
Randomized No
FilterWire EZ
(n ¼ 17) p2 Value
Baseline NIRS measures
LCBI 143.2 (74.3–236.4) 91.3 (49.1–133.6) 242.2 (205.3–356.4) <0.0001 242.2 (205.3–382.6) 245.4 (199.6–353.5) 0.90
MaxLCBI4mm 448.4 (274.8–654.4) 336.0 (183.8–422.2) 672.9 (615.8–789.2) <0.0001 665.9 (619.6–726.0) 683.6 (615.8–789.2) 0.58
Baseline IVUS measures at the MLA
site within the total lesion
Distance from the ostium, mm 1 (11.3–29.5) 16.6 (10.9–29.5) 19.8 (11.8–31.4) 0.53 18.0 (11.5–27.4) 20.5 (11.8–41.6) 0.50
EEM CSA, mm2 12.3 (8.9–15.1) 12.0 (8.9–14.5) 12.6 (8.6–15.7) 0.76 13.1 (10.0–17.7) 11.8 (8.6–14.7) 0.47
P&M CSA, mm2 9.9 (6.8–12.5) 9.4 (6.8–11.9) 10.6 (6.7–13.6) 0.54 10.8 (8.5–14.6) 10.3 (6.4–12.5) 0.48
Lumen area, mm2 2.3 (1.9–3.1) 2.4 (1.9–3.1) 2.2 (1.8–2.9) 0.35 2.2 (1.9–3.1) 2.2 (1.7–2.8) 0.63
Plaque burden, % 79.6 (74.1–84.9) 77.5 (72.4–84.5) 80.8 (75.7–85.0) 0.22 80.8 (78.9–85.0) 80.3 (75.5–85.0) 0.69
Attenuated plaque present
(total lesion)
75 (90.4%) 46 (88.5%) 29 (93.5%) 0.70 12 (85.7%) 17 (100%) 0.20
Length, mm 14.2 (6.9–26.4) 10.2 (4.2–18.1) 24.3 (13.6–38.0) <0.0001 20.6 (10.9–26.4) 28.0 (20.3–43.0) 0.11
Maximal angle, degrees 127 (97–210) 107 (80–140) 214 (121–278) <0.0001 211 (76–278) 214 (185–261) 0.36
Baseline IVUS measures at the MLA
site within the maxLCBI4mm
segment
Distance from the ostium, mm 14.8 (9.9–28.1) 14.4 (9.6–28.9) 16.5 (11.3–27.3) 0.71 13.5 (11.0–21.1) 17.5 (11.3–32.8) 0.50
EEM CSA, mm2 12.9 (10.1–15.2) 12.6 (9.6–14.9) 13.6 (10.5–16.6) 0.28 15.1 (11.5–17.1) 12.9 (10.5–14.9) 0.34
P&M CSA, mm2 9.6 (7.0–12.2) 8.6 (6.7–10.9) 11.0 (7.6–13.3) 0.05 11.7 (9.2–14.9) 9.8 (7.6–12.7) 0.32
Lumen area, mm2 2.8 (2.2–3.7) 3.0 (2.2–4.2) 2.6 (2.2–3.3) 0.25 2.7 (2.2–3.7) 2.6 (2.2–3.2) 0.65
Plaque burden, % 76.1 (68.1–82.6) 71.7 (64.9–81.3) 80.0 (75.2–82.8) 0.02 79.9 (75.2–82.6) 80.1 (76.0–82.8) 0.87
Lipid-rich P&M CSA,* mm2 4.8 (2.3–7.7) 3.4 (1.4–5.2) 8.9 (5.9–10.4) <0.0001 10.0 (6.1–13.4) 7.7 (5.8–9.7) 0.16
Lipid-rich plaque burden,* % 41.2 (19.1–62.4) 25.9 (10.1–42.4) 63.6 (56.0–68.9) <0.0001 63.5 (56.0–75.4) 63.6 (56.2–66.7) 0.51
Values are median (interquartile range). *See Online Figure 2.
IVUS ¼ intravascular ultrasound; MLA ¼ minimal luminal area; NIRS ¼ near-infrared spectroscopy; EEM ¼ external elastic membrane; CSA ¼ cross-sectional area; LCBI ¼ lipid core burden index; P&M ¼
plaque þ media; MaxLCBI4mm ¼ maximal lipid core burden index over any 4 mm segment; other abbreviations as in Table 1.
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932Angiography and Interventions clinically relevant MI
deﬁnition (3) occurred in 14 of 85 (16.5%) and 2 of 85
(2.4%) patients, respectively. There were no other in-
hospital major adverse cardiac events.am of Peak Post-PCI Biomarker Elevations in the
tion
veloped in 21 of 85 patients (24.7%). CK-MB ¼ creatine kinase-
¼ myocardial infarction; PCI ¼ percutaneous coronary intervention;
f normal.CORRELATESOF PERIPROCEDURALMI. The univariable
correlations between baseline clinical and lesion-
related features and periprocedural MI were exam-
ined for all the variables listed in Tables 1 to 3,
with the positive associations displayed in Table 4.
No clinical or angiographic characteristics were pre-
dictive of periprocedural MI. A small baseline MLA
was associated with periprocedural MI. Baseline LCBI
and maxLCBI4mm were positively correlated with
periprocedural MI (C statistic of 0.64 and 0.63,
respectively, with cutoffs of 144 and 388, respec-
tively). Figure 4 demonstrates the chemogram for
each lesion in the study and its relationship to peri-
procedural MI. The predictive value for periproce-
dural MI was strengthened by considering the degree
of plaque burden within the maxLCBI4mm segment
(Table 4). In this regard, there was only a weak cor-
relation between maxLCBI4mm and plaque burden at
the maxLCBI4mm site (Figure 5).
OUTCOMES ACCORDING TO RANDOMIZATION. The
FilterWire EZ was successfully deployed before PCI
in 13 of 14 patients (92.9%) randomized to distal
embolic protection. Periprocedural MI after stenting
occurred in 5 of 14 patients (35.7%) assigned to
TABLE 4 Correlates of Periprocedural MI
MI
(n ¼ 21)
No MI
(n ¼ 64) C Statistic p Value
Baseline NIRS measures
LCBI 194.0 (125.7–252.2) 124.7 (58.3–215.7) 0.64 0.05
MaxLCBI4mm 481.5 (425.6–679.6) 371.5 (228.9–611.6) 0.63 0.05
Baseline IVUS measures at
the MLA site within
the total lesion
Lumen area, mm2 2.1 (1.7–2.4) 2.5 (2.0–3.1) 0.67 0.03
Baseline IVUS measures at
the MLA site within
the maxLCBI4mm
segment
Lumen area, mm2 2.3 (1.8–3.4) 3.0 (2.4–4.1) 0.67 0.02
Plaque burden, % 78.3 (72.3–87.0) 75.5 (66.2–81.3) 0.66 0.04
Lipid-rich P&M CSA, mm2 6.2 (4.6, 11.2) 4.0 (1.4, 7.6) 0.71 0.006
Lipid-rich plaque
burden, %
56.6 (42.7, 67.5) 32.9 (10.6, 59.4) 0.73 0.003
Values are median (interquartile range). Univariable correlations of periprocedural MI were tested for all the
variables in Tables 1 through 3. The p values for those variables not listed here were >0.05. These ﬁndings were
consistent in the single high-enrolling site and the lower enrolling sites.
MI ¼ myocardial infarction; other abbreviations as in Table 3.
FIGURE 4 Baseline Chemograms From All 85 Patients
The cases are ordered from the highest maxLCBI4mm (top left corner) to the lowest
maxLCBI4mm (lower right corner), with the vertical line dividing those patients in the
randomized cohort (maxLCBI4mm $600) and the registry (maxLCBI4mm <600). The
asterisks represent those chemograms with a periprocedural myocardial infarction. Using
the pre-speciﬁed cutoff of maxLCBI4mm $600 to deﬁne a lipid-rich plaque (LRP), peri-
procedural myocardial infarction developed in 9 of 31 (29.0%) LRPs compared with 12 of
54 (22.2%) non-LRPs (relative risk: 1.31, 95% conﬁdence interval: 1.31; interquartile range,
0.62 to 2.75; p ¼ 0.48). Abbreviations as in Figure 1.
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933PCI þ FilterWire EZ compared with 4 of 17 patients
(23.5%) assigned to PCI alone (relative risk: 1.52, 95%
conﬁdence interval: 0.50 to 4.60; p ¼.69). The single
patient who did not have the FilterWire placed did
not experience an MI. There were no signiﬁcant dif-
ferences in periprocedural myonecrosis between the
2 groups regardless of the threshold level of
biomarker elevation (Figure 6). Of note, among the 14
patients assigned the FilterWire EZ, 8 (57.1%) of the
target lesions were bifurcations, although by quanti-
tative coronary angiography the median (interquartile
range [IQR]) reference vessel diameter of the side
branches was only 2.1 mm (1.8 to 2.5 mm). In addition,
by quantitative coronary angiography, there was an
additional median of 2 side branches (IQR: 1 to 3)
between the lesion and the ﬁlter loop, with a reference
vessel diameter of 2.2 mm (IQR: 2.1 to 2.5 mm).
A representative case where small side branches were
lost after stenting a LRP is shown in Online Figure 3.
DISCUSSION
The present report describes the outcomes of the ﬁrst
prospective, multicenter investigation seeking to
determine whether lesions at risk of periprocedural
myonecrosis could be prospectively identiﬁed by
intravascular imaging and whether a distal embolic
protection ﬁlter might reduce periprocedural MI after
stenting of high-risk plaques. The major results of our
study are the following. 1) Plaques responsible for
periprocedural myonecrosis were lipid rich and had a
large plaque burden and a small MLA. 2) Nonetheless,
a substantial proportion of MIs arose from non-LRPs.
3) The use of a distal embolic protection ﬁlter did not
reduce the rate of periprocedural MI after stenting
of LRPs.
Intraprocedural complications of stenting, in-
cluding distal embolization, side-branch closure, no-
reﬂow, and other thromboembolic phenomena, are
increased in patients with troponin-positive acute
coronary syndromes; in larger vessels and in those
with reduced Thrombolysis in Myocardial Infarction
ﬂow and myocardial blush; in lesions with thrombus
and other complex features; and in more severe ste-
noses (5–7). Predicting (and preventing) periproce-
dural complications in patients in stable condition
without these high-risk features has proven elusive.
Previous case reports and uncontrolled series have
suggested that plaques with high lipid content and/or
a thin ﬁbrous cap might be prone to embolization and
periprocedural MI and that such ﬁbroatheromas may
be detected by several intravascular imaging modal-
ities (10–16). These observations had heretofore not
been prospectively validated.In the present study, we used NIRS to identify
LRPs in a stable patient cohort, more than 90% of
whom presented with troponin-negative coronary
syndromes and had angiographically noncomplex le-
sions. Both the total lesion LCBI and maxLCBI4mm
FIGURE 5 Correlation Between maxLCBI4mm and Plaque
Burden at the Minimal Luminal Area Site Within the
maxLCBI4mm Segment
The red dots represent cases with periprocedural myocardial
infarction. The blue dots represent cases without periprocedural
myocardial infarction. *Coefﬁcient represents an increase of 10
units. The regression model met the criteria for linearity ac-
cording to the Harvey-Collier test for linearity (p ¼ 0.96).
maxLCBI4mm ¼ maximal lipid core burden index over any 4-mm
length.
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934parameters were predictive of periprocedural MI after
PCI. Our ﬁndings support the hypothesis that distal
embolization with microvascular obstruction un-
derlies many of these events as both lipid measures
at the plaque site were markedly reduced after
stent implantation. Compared with gray-scale IVUS,FIGURE 6 Periprocedural Myocardial Infarction After Randomizatio
There was no signiﬁcant difference in the rate of periprocedural MI betw
other threshold deﬁnition of MI (right). CI ¼ conﬁdence interval; RR ¼radiofrequency IVUS, and optical coherence tomog-
raphy (all of which require substantial operator or
technician involvement to draw contours, measure
dimensions, and interpret morphology), LCBI and
maxLCBI4mm parameters are fully automated and
quantitative and are generated in real time during
catheter pullback, facilitating assimilation into the
cath lab workﬂow without requiring complex image
interpretation or introducing excessive delays. None-
theless, in our study, gray-scale IVUS offered comple-
mentary predictive utility by identifying lesions with a
high plaque burden and/or small MLA, which when
combined with lipid parameters (as reﬂected in a high
LRP burden) may identify lesions at particularly high
risk. Future studies are required to determine whether
optical coherence tomography would provide addi-
tional prognostic information to NIRS-IVUS.
Although the present study has now validated the
previously conjectured correlation between greater
plaque lipid content and peri-PCI MI (15,16), the
relationship was modest, and more than half of MIs
arose from lesions that were below the pre-speciﬁed
maxLCBI4mm cutoff of $600. Selecting a lower cut-
off value would increase sensitivity although re-
ducing speciﬁcity and positive predictive value. In
this regard, different cutoff values may be desirable
for different applications. However, not all peri-
procedural MIs are due to distal embolization. Loss of
side branches arising from the lesion may also be
caused by plaque or carina shift. Periprocedural MI
may also be due to other angiographic complications
such as severe dissection or vasospasm, perforation,
or intraprocedural stent thrombosis.n to PCI þ FilterWire EZ Versus PCI Alone
een the 2 groups according to the protocol deﬁnition (left) or by any
relative risk; other abbreviations as in Figures 2 and 3.
PERSPECTIVES
WHAT IS KNOWN? Distal embolization and periprocedural
myocardial infarction may occur after percutaneous coronary
intervention of lipid-rich plaque.
WHAT IS NEW? Lipid-rich plaques that have increased risk to
cause periprocedural myonecrosis can be identiﬁed by a combi-
nation intravascular ultrasound and near-infrared spectroscopy
imaging catheter before stent implantation. However, use of a
distal protection ﬁlter before stenting such high-risk lesions may
not be protective.
WHAT IS NEXT? Further studies are warranted to determine
whether potent antiplatelet agents or embolic protection stents
might be protective in patients with lesions at high-risk of distal
embolization and other periprocedural complications.
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935Use of the FilterWire EZ did not prove effective in
reducing periprocedural myonecrosis after stenting
of LRPs. Although the reasons for this are uncertain,
ﬁlter devices are unable to protect side branches
arising from the target lesion or between the lesion
and the ﬁlter landing zone. Although we excluded
true bifurcation lesions and large side branches in the
distal segment adjacent to the stenosis, small side
branches were present in the majority of lesions that
were unprotected. Additional study is warranted to
determine whether there might be a role for GPIIb/IIIa
inhibitors or other potent antiplatelet agents in pre-
venting myonecrosis after PCI of LRPs.
STUDY LIMITATIONS. First, a sensitive deﬁnition was
used to deﬁne periprocedural MI (post-PCI biomarker
elevation to 3 or more times the upper limit of
normal) for this proof of principle study. Not all of
these MIs are of clinical consequence (3), although it
is likely that the same predictive factors are related to
larger clinically relevant post-procedure MIs as well,
at least those due to distal embolization. Second,
because the present study was designed principally to
examine periprocedural events, patients were not
routinely followed beyond the in-hospital phase.
Third, ﬁlter contents were not routinely analyzed,
and thus we cannot speak to the quantity and makeup
of captured debris. Fourth, only 36.5% of lesions were
protocol-deﬁned LRPs, somewhat less than the 50%
anticipated, which may have been due to enrollment
of mostly biomarker-negative patients. Similarly, the
29.0% periprocedural MI rate after PCI of LRPs was
lower than anticipated, possibly due to the charac-
teristics of the patients and lesions studied, as well as
the modest relationship between NIRS-deﬁned lipid
parameters and periprocedural myonecrosis. It is also
possible that the distal protection ﬁlter might have
been more successful in preventing distal emboliza-
tion and myonecrosis had the lesions been even more
lipid rich than in this study and with a thrombotic
component, as was present in the report by Brilakis
et al. (19). The ﬁfth and most important limitation
relates to the study size. Determining the lesion-
speciﬁc characteristics responsible for periproce-
dural MI required enrolling patients undergoing PCI
of single, noncomplex, native coronary artery steno-
ses in patients with normal baseline biomarkers. In
addition, anatomic criteria had to be met for Filter-
Wire use. A large number of patients had to be
screened to identify such lesions, and the ﬁnal sam-
ple size was modest. However, the trial was halted
early for futility of the randomized therapy, and with
95% conﬁdence, we were able to exclude a more than
50% treatment effect of the FilterWire in preventingperiprocedural myonecrosis, the minimal effect size
that might have warranted a pivotal randomized trial
for this application. Moreover, the present study size
was sufﬁcient to conﬁrm the hypothesized relation-
ship between NIRS-identiﬁed LRPs and periproce-
dural myonecrosis. Nonetheless, a larger cohort
would have provided greater precision, may have
revealed additional correlates of periprocedural MI,
and would have accommodated multivariable and
subgroup analyses.
CONCLUSIONS
Pre-interventional intravascular imaging with a com-
bined NIRS-IVUS catheter is able to identify lesions at
increased risk of periprocedural myonecrosis. Such
plaques are lipid rich and have high plaque burden
and/or a small cross-sectional area. However, not all
periprocedural MIs are caused by distal embolization,
and the clinical utility of any single parameter to pre-
dict periprocedural MI is modest. Finally, a distal
embolic protection ﬁlter is unlikely to be of use in
reducing periprocedural myonecrosis after PCI of most
LRPs in native coronary arteries. Further studies are
warranted to determine whether potent antiplatelet
agents such as cangrelor (24) and embolic protection
stents (25) might have speciﬁc utility in patients with
lesions at high risk of distal embolization and other
periprocedural complications.
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